PepGen announces first patient dosed in CONNECT1-EDO51 Phase 2 trial

PepGen announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose clinical trial evaluating PGN-EDO51 for the treatment of Duchenne muscular dystrophy patients amendable to an exon 51 skipping therapy. “We are pleased to have dosed the first patient in our CONNECT1-EDO51 clinical trial, which marks another milestone in our commitment to developing therapies with the potential to truly improve the lives of people living with DMD,” said James McArthur, Ph.D., President and CEO of PepGen. “Based on the levels of exon skipping achieved following a single dose of PGN-EDO51 in our Phase 1 healthy volunteer trial, we are looking forward to our initial planned data readout in DMD patients at the 5 mg/kg PGN-EDO51 dose level for CONNECT1-EDO51 in the middle of 2024.”